BioCentury | Jul 11, 2016
Clinical News

CHS-131: Phase IIb data

...Phase IIb trial in 227 treatment-naive patients with RRMS showed that once-daily 3 mg oral CHS-131...
...endpoint vs. placebo. Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif. Product: CHS-131 (formerly INT-131 , INT131...
BioCentury | Jun 29, 2016
Clinical News

Coherus' CHS-131 meets Phase IIb MS endpoint

...Coherus BioSciences Inc. (NASDAQ:CHRS) said a 3 mg dose of CHS-131 met the primary endpoint of...
...227 treatment-naive patients. The company said the overall adverse event profiles were "relatively similar" for CHS-131...
...evidence of immune suppression. Detailed data are to be presented at a conference this year. CHS-131...
BioCentury | Apr 2, 2015
Financial News

Coherus raises $120M in follow-on

...candidates and $7 million to fund a Phase II study it began last month of INT-131...
...TZD) peroxisome proliferation activated receptor (PPAR) gamma selective modulator, to treat multiple sclerosis. Coherus acquired INT-131...
BioCentury | Sep 8, 2011
Cover Story

PPARgamma: none is more

...Phase II testing. Metabolex Inc. 's arhalofenate ( MBX-102 ) and InteKrin Therapeutics Inc. 's INT131...
...of efficacy. The company is running a Phase II trial of the compound in gout. INT131...
BioCentury | Aug 12, 2010
Cover Story

Resolving the PPARgamma paradox

...mechanism may explain how partial PPARg agonists in clinical development, including InteKrin Therapeutics Inc. 's INT131...
...referred to as selective PPAR modulators (SPPARMs) and include Metabolex Inc. 's MBX-102 and InteKrin's INT131...
...failure and bone fracture," said Linda Higgins, president and CEO of InteKrin. "SPPARMs such as INT131...
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Endocrine disease

...pioglitazone from Takeda Pharmaceutical Co. Ltd. are marketed to treat diabetes. The selective PPARg modulator INT131...
BioCentury | Oct 5, 2009
Clinical News

INT131: Phase IIb data

...U.S. and Mexican Phase IIb INT131-007 trial in 366 Type II diabetics showed that oral INT131...
...Indianapolis, Ind.) in various countries in Europe, Asia and other regions. The company also said INT131...
...compared with Actos. Specifically, there was no difference in incidence or severity of edema between INT131...
BioCentury | Oct 1, 2009
Clinical News

InteKrin's INT131 meets diabetes endpoint

...InteKrin Therapeutics Inc. (Los Altos, Calif.) reported that oral INT131 met the primary endpoint of significantly...
...weeks in the Phase IIb INT131-007 trial to treat Type II diabetes (p<0.0001). InteKrin said INT131's...
...that shown by active-comparator Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). InteKrin also said INT131...
BioCentury | Mar 16, 2009
Clinical News

INT131: Completed Phase IIb enrollment

...a double-blind, placebo-controlled, U.S. and Mexican Phase IIb trial (INT131-007) evaluating 4 dosages of oral INT131...
...Osaka, Japan) and Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.). InteKrin licensed exclusive rights to INT131...
...2007). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. InteKrin Therapeutics Inc. , Los Altos, Calif. Product: INT131...
BioCentury | Aug 5, 2008
Financial News

InteKrin raises $18 million

...raise the remaining amount in a second closing by the end of the month. InteKrin's INT131...
Items per page:
1 - 10 of 38